• FDA granted Breakthrough Device Designation to HeartBeam for its HeartBeam System to support at-home assessment of suspected heart attacks.
• Status sets up prioritized FDA engagement ahead of a planned multicenter pivotal study to expand the system’s indications.
• Designation could also support an expedited Medicare coverage pathway once the device receives clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartbeam Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610050831BIZWIRE_USPR_____20261005_BW403356) on October 05, 2026, and is solely responsible for the information contained therein.